Work

A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.2500

Authors: Geoffrey Shapiro, Lee S. Rosen, Anthony W. Tolcher, Jonathan Wade Goldman, Leena Gandhi, Kyriakos P. Papadopoulos, Sara M. Tolaney, Muralidhar Beeram, Drew Warren Rasco, Palaniappan Kulanthaivel, Qian Li, Tianle Hu, Damien Cronier, Edward M Chan, Keith Flaherty, Patrick Y. Wen, Amita Patnaik

Institutions: Dana-Farber Cancer Institute, University of California, Los Angeles, South Texas Accelerated Research Therapeutics, Eli Lilly (United States), Harvard University, Massachusetts General Hospital

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3011926296

Cites:

Cited by: 66

Related to: 10